35 Gatehouse Drive
9 articles about Corvidia Therapeutics
Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
June 11, 2020 13:20 UTC Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS--( BUSINESS WIRE )-- Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 bi
Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab
Ablexis Announces Licensing Agreement with Corvidia Therapeutics
Ablexis grants rights to Corvidia to use the AlivaMab Mouse™ platform for research, development and potential commercialization of antibodies
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
Corvidia Therapeutics, headquartered in Waltham, Massachusetts, closed on a Series B funding round worth $60 million.
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work
Lead investor Venrock joined by Andera, Cormorant, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH, Sofinnova Partners, Apple Tree Partners and MedImmune
Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer
Corvidia Therapeutics Inc. announced the appointment of Marc de Garidel as Chief Executive Officer. Mr. de Garidel succeeds Corvidia’s Michael Davidson, M.D., who will remain on the company’s executive team as Chief Scientific Officer.
Corvidia Therapeutics Bags $26 Million and a Licensing Deal with AstraZeneca PLC